Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cytomegalovirus-specific CD8+ T-cell responses are associated with arterial blood pressure in people living with HIV

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Making the best of the worst: Care quality during emergency cesarean sections

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Seasonality of ventricular fibrillation at first myocardial infarction and association with viral exposure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prevalence, type distribution, and risk factors for oral HPV in Danish renal transplant recipients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. BAYESIAN ANALYSIS OF BASELINE RISK OF CIN2 AND ≥CIN3 BY HPV GENOTYPE IN A EUROPEAN REFERRAL COHORT

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
New commercially available Human Papillomavirus (HPV) assays need to be evaluated in a variety of cervical screening settings. Cobas HPV Test (cobas) is a real-time PCR-based assay allowing for separate detection of HPV genotypes 16 and 18 and a bulk of 12 other high-risk genotypes. The aim of the present study, Horizon, was to assess the prevalence of high-risk HPV infections in an area with a high background risk of cervical cancer, where women aged 23-65 years are targeted for cervical screening. We collected 6,258 consecutive cervical samples from the largest cervical screening laboratory in Denmark serving the whole of Copenhagen. All samples were stored in SurePath media. In total, 5,072 samples were tested with cobas, Hybrid Capture 2 High Risk HPV DNA test (HC2) and liquid-based cytology. Of these, 27% tested positive on cobas. This proportion decreased by age, being 43% in women aged 23-29 years and 10% in women aged 60-65 years. HC2 assay was positive in 20% of samples, and cytology was abnormal (≥ atypical squamous cells of undetermined significance) for 7% samples. When only samples without recent abnormalities were taken into account, 24% tested positive on cobas, 19% on HC2, and 5% had abnormal cytology. The proportion of positive cobas samples was higher than in the ATHENA trial. The age-standardized cobas positivity vs. cytology abnormality was 3.9 in our study and 1.7 in ATHENA. If in Copenhagen the presently used cytology would be replaced by cobas in women above age 30 years, an extra 11% of women would based on historical data be expected to have a positive cobas test without an underlying cervical intraepithelial lesion grade 3 or worse. Countries with a high prevalence of HPV infections should therefore proceed to primary HPV-based cervical screening with caution.
OriginalsprogEngelsk
TidsskriftP L o S One
Vol/bind8
Udgave nummer3
Sider (fra-til)e59765
ISSN1932-6203
DOI
StatusUdgivet - 2013

ID: 38666408